[HTML][HTML] A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Y Qi, J Li, S Lin, S Wu, K Chai, X Jiang, J Qian… - Scientific Reports, 2024 - nature.com
Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is …
Severe hepatotoxicity during treatment with capmatinib
CM Valencia Soto, V Martínez Callejo… - Journal of Oncology …, 2023 - journals.sagepub.com
Introduction Capmatinib is a mesenchymal-epithelial transition (MET) inhibitor authorized for
metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation …
metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation …
[HTML][HTML] A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) …
R Sun, Z Ning, H Qin, W Zhang, Y Teng, C Jin, J Liu… - Scientific Reports, 2024 - nature.com
Amivantamab is the first dual-specificity antibody targeting EGFR and MET, which is
approved for the treatment of locally advanced or metastatic non-small cell lung cancer …
approved for the treatment of locally advanced or metastatic non-small cell lung cancer …
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
W Li, W Wang - Investigational New Drugs, 2024 - Springer
MET exon 14 skipping alterations and MET amplifications are recognized as oncogenic and
targetable genetic changes in cancer patients. The treatment of MET-selective tyrosine …
targetable genetic changes in cancer patients. The treatment of MET-selective tyrosine …
Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
K Kunimasa, T Kawamura, M Tamiya, T Inoue… - Thoracic …, 2021 - Wiley Online Library
Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were
approved by the Food and Drug Administration (FDA) for the treatment of metastatic non …
approved by the Food and Drug Administration (FDA) for the treatment of metastatic non …
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
L Peng, K Xiao, S Ottaviani, J Stebbing… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Background Baricitinib is approved for the treatment of rheumatoid arthritis (RA). The
authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting …
authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting …
Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
X Chen, X Cui, N Pognan, M Quinlan… - British journal of …, 2022 - Wiley Online Library
Aims Capmatinib, a mesenchymal–epithelial transition factor tyrosine kinase inhibitor, is
metabolized by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. In individuals with …
metabolized by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. In individuals with …
[HTML][HTML] Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
Y Zhang, L Ran, Y Liang, Y Zhang, Z An - Frontiers in Pharmacology, 2023 - frontiersin.org
Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor
of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and …
of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and …
Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System
D Zhao, X Long, J Wang - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Background To data, there is insufficient large-scale data on the adverse events (AEs) of
pemigatinib. Consequently, we conducted a pharmacovigilance study utilizing the Food and …
pemigatinib. Consequently, we conducted a pharmacovigilance study utilizing the Food and …
[HTML][HTML] MO01. 04 Management of selected adverse events with capmatinib: Institutional experiences from the GEOMETRY Mono-1 trial
K Goodwin, B Ledezma, R Heist, E Garon - Journal of Thoracic Oncology, 2021 - jto.org
Background Capmatinib is approved in the United States and Japan for adults with
metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to …
metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to …